Paclitaxel

Confirming previously presented earlier results, a paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis.

Warnings about excess mortality risk with paclitaxel-coated devices to treat peripheral artery disease are “no longer supported,” based on a updated review of relevant trial data, according to an FDA announcement.

Surmodics announced that the FDA has approved its low-dose paclitaxel-coated balloon for certain patients with peripheral artery disease.

The use of low-intensity pulsed ultrasound with concomitant administration of IV microbubbles can improve the delivery of albumin-bound paclitaxel and carboplatin through the blood-brain barrier, study results showed.

Adjuvant paclitaxel and trastuzumab continued to appear effective after 10 years of follow up among patients with small node-negative, HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

A novel low-dose paclitaxel-coated balloon was noninferior to a higher-dose paclitaxel-coated balloon at 24 months in patients with peripheral artery disease, according to new data from the TRANSCEND trial.

In this video, Andrew Ciupek, PhD, discusses findings from the Alliance trial, IMpower010 and NADIM-2.

Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2

Prespecified, real-world study assessing long-term safety of paclitaxel-coated devices vs. non-paclitaxel-coated devices for femoropopliteal artery revascularization in PAD.

Induction chemotherapy with paclitaxel, cisplatin and capecitabine vs. cisplatin and fluorouracil improved failure-free survival among patients with advanced nasopharyngeal carcinoma, according to a study published in JAMA Oncology.